Pharma stocks priced in policy impact: Nirmal Bang
The final decision to introduce price caps in the pharma sector is only marginally more negative than the previous formula, says Praful Bohra, senior research analyst of pharmaceuticals at Nirmal Bang. The pricing would be based on a simple average of drugs with more than 1 per cent market share. He says that with the impact of the price caps already been factored in by the markets, stocks would see a correction only if combinations are also brought under price caps.
